

Please type a plus sign (+) inside this box ☐

08-17-08

IFW 163

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number 10/575,296

Filing Date October 14, 2004

First Named Inventor Kingston Mills

Group/Art Unit Unassigned

Examiner Name Unassigned

Total Number of Pages in This Submission

Attorney Docket Number 43369-0002

## ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Response

☐ After Final

☐ Version With Markings Showing  
Changes

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☒ Information Disclosure Statement w/15  
References

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/ Incomplete  
Application

☐ Response to Missing  
Parts under 37 CFR  
1.52 or 1.53

☐ Copy of Notice

☐ Copy of an Assignment

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition Routing Slip (PTO/SB/69)  
and Accompanying Petition

☐ Petition to Convert to a  
Provisional Application

☐ Power of Attorney, by Assignee to  
Exclusion of Inventor Under 37 C.F.R.  
§3.71 With Revocation of Prior Powers

☐ Terminal Disclaimer

☐ Small Entity Statement

☐ Request for Refund

☐ After Allowance Communication to  
Group

☐ Appeal Communication to Board of  
Appeals and Interferences

☐ Proprietary Information

☐ Status Letter

☐ ADDITIONAL ENCLOSURE(S)  
(PLEASE IDENTIFY BELOW):

☒ RETURNED STAMPED POSTCARD

Remarks

**AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN  
CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 43369-0002**

## SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	HELLER EHRMAN LLP	JAMES A. FOX (Reg. No. 38,455)
	275 Middlefield Road, Menlo Park, California 94025	Telephone: (650) 324-7000 Facsimile: (650) 324-0638
Signature		
Date	August 15, 2006	Customer Number: 25213


## CERTIFICATE OF EXPRESS MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: MAIL STOP xxxxx, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: August 15, 2006.x

Express Mail Label EV 765 972 667 US

Typed or printed name	ELENA TORRES		
Signature		Date	August 15, 2006

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop \_\_\_, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF EXPRESS MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below.			
Express Mail Label: EV 765 972 667 US			
Typed or print name	Elena Torres		
Signature		Date	August 15, 2006



PATENT

Attorney Docket No.: 43369-0002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**PATENT APPLICATION**

Inventor(s): Kingston Mills et al.

Application No.: 10/575,296

Filed: October 14, 2004

Title: ADENYLATE CYCLASE IN THE TREATMENT  
AND/OR PROPHYLAXIS OF IMMUNE-  
MEDIATED DISEASE

Art Unit: Unassigned

Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. §1.97**

Mail Stop: AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 43369-0002).

Respectfully submitted,


HELLER EHRMAN LLP

By: 

JAMES A. FOX  
Reg. No.: 38,455

Dated: August 15, 2006

HELLER EHRMAN LLP  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Telephone: 1.650.324.7115  
Facsimile: 1.650.324.0638  
Customer No.: 25213


**INFORMATION DISCLOSURE  
STATEMENT**
**PTO-1449**
**ATTY. DOCKET NO.**

43369-0002

**SERIAL NO.**

10/575,296

**APPLICANT:** Kingston Mills et al.

**FILING DATE:** 010/14/2004

**GROUP:** Unassigned

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,183,745	02/02/1993	Danchin et al.	435	69.1	
	5,237,052	08/17/1993	Novotny	530	350	
	5,503,829	04/02/1996	Ladant et al.	424	192.1	
	5,679,784	10/21/1997	Ladant et al.	536	23.7	
	5,595,901	01/21/1997	Rocancourt et al.	435	232	
	5,935,580	08/10/1999	Ladant et al.	424	192.1	
	6,030,625	02/29/2000	Gueirard et al.	424	253.1	
	6,127,151	10/03/2000	Novotny et al.	435	71.1	
	6,210,685	04/03/2001	Novotny et al.	424	254.1	
	6,309,648	10/30/2001	Betsou et al.	424	203.1	
	6,387,377	05/14/2002	Gueirard et al.	424	240.1	
	6,582,705	06/24/2003	Gueirard et al.	424	240.1	
	6,759,241	07/06/2004	Hone et al.	435	325	
	2002/0146430	10/10/2002	Galen	424	200.1	
	2002/0150595	10/17/2002	Novotny et al.	424	237.1	
	2003/0077294	04/24/2003	Novotny et al.	424	190	
	2003/0108572	06/12/2003	Novotny et al.	424	237.1	
	2004/0001867	01/01/2004	Leclerc et al.	424	253.1	

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	93/21324	28/10/1993	WO			<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**


	Dadaglio et al., "Induction of a Polarized Th1 Response by Insertion of Multiple Copies of a Viral T-Cell Epitope into Adenylate Cyclase of <i>Bordetella Pertussis</i> ", Infection and Immunity, July 2000, pp. 3867-3872.
	El-Azami-El-Idrissi et al., "Interaction of <i>Bordetella Pertussis</i> Adenylate Cyclase with CD11b/CD18", J. Biol. Chem. 278 (40):38514-38521 (2003).
	Fayolle et al., "Delivery of Multiple Epitopes by Recombinant Detoxified Adenylate Cyclase of <i>Bordetella Pertussis</i> Induces Protective Antiviral Immunity", Journal of Virology, August 2001, pp. 7330-7338.
	Gamvrellis et al., "Vaccines that Facilitate Antigen Entry into Dendritic Cells", Immunology and Cell Biology 82(5):506-516 (2004).

**EXAMINER**
**DATE CONSIDERED**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SV 2226385 v1

8/11/06 11:07 AM (43369-0002)


**INFORMATION DISCLOSURE  
STATEMENT**
**PTO-1449**
**ATTY. DOCKET NO.**

43369-0002

**SERIAL NO.**

10/575,296

**APPLICANT:** Kingston Mills et al.

**FILING DATE:** 10/14/2004

**GROUP:** Unassigned

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Gmira et al., "Characterization of Recombinant <i>Bordetella Pertussis</i> Adenylate Cyclase Toxins Carrying Passenger Proteins", Res. Microbiol. 152:889-900 (2001).
	Guermonprez et al., "Les Toxins Bacteriennes Recombinants: De Nouveaux Vecteurs Pour La Vaccination?", Medecine/Sciences 2000; 16:653-662.
	Guermonprez et al., "Direct Delivery of the <i>Bordetella Pertussis</i> Adenylate Cyclase Toxin to the MHC Class I Antigen Presentation Pathway", The Journal of Immunology, 162:1910-1916 (1999).
	Guermonprez et al., "In Vivo Receptor-Mediated Delivery of a Recombinant Invasive Bacterial Toxoid to Cd11c <sup>+</sup> CD8 <sup>+</sup> CD11b <sup>high</sup> Dendritic Cells", Eur. J. Immunol 32(11):3071-3081 (2002).
	Hormozi et al., "Adjuvant and Protective Properties of Native and Recombinant <i>Bordetella Pertussis</i> Adenylate Cyclase Toxin Preparations in Mice", FFMS Immunology and Medical Microbiology 23:273-282 (1999).
	Karimova et al., "Charge-Dependent Translocation of <i>Bordetella Pertussis</i> Adenylate Cyclase Toxin into Eukaryotic Cells: Implication for the In Vivo Delivery of CD8 <sup>+</sup> T Cells Epitopes into Antigen-Presenting Cells", Proc. Natl. Acad. Sci. USA vol. 95, pp. 12532-12537 (1998).
	Lavelle et al., "Molecules of Infectious Agents as Immunomodulatory Drugs", Current Topics in Medicinal Chemistry 4:499-508 (2004).
	Ross et al., "Adenylate Cyclase Toxin from <i>Bordetella Pertussis</i> Synergizes with Lipopolysaccharide to Promote Innate Interleukin-10 Production and Enhances the Induction of Th2 and Regulatory T Cells", Infection and Immunity, pp. 1568-1579 (2004).
	Saron et al., "Anti-Viral Protection Conferred by Recombinant Adenylate Cyclase Toxins from <i>Bordetella Pertussis</i> Carrying a CD8 <sup>+</sup> T Cell Epitope from Lymphocytic Choriomeningitis Virus", Proc. Natl. Acad. Sci. USA vol. 94, pp. 3314-3319 (1997).
	Simsova et al., "The Adenylate Cyclase Toxin from <i>Bordetella Pertussis</i> -A Novel Promising Vehicle for Antigen Delivery to Dendritic Cells", International Journal of Medical Microbiology 293 (7-8):571-576 (2004).
EXAMINER	
DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.